Trials overview
We are currently investigating BPL-003 (our novel intranasal formulation of 5-MeO-DMT) and ELE-101 (our novel intravenous formulation of psilocin) for Treatment Resistant Depression, Major Depressive Disorder and Alcohol Use Disorder.
Condition
Status
Product
Phase
Sex & age range
Location(s)
Link
Treatment Resistant Depression
Recruiting
BPL-003
IIb
M + F
18 – 75 years
Australia, Germany, Poland, Spain, UK, US
Major Depressive Disorder
Recruiting
ELE-101
IIa
M + F
18 – 65 years
Manchester, UK, Liverpool, UK
Phase IIb study of BPL-003 in patients with Treatment Resistant Depression
Recruiting
This randomised, dose-finding study will evaluate the effects of a single medium or high dose of BPL-003 against an active placebo in patients with moderate to severe Treatment Resistant Depression (TRD), alongside psychological support. It is taking place at over 40 sites across Australia, Germany, Poland, Spain, the United Kingdom and the United States.
Phase IIa adjunctive study of BPL-003 in patients with Treatment Resistant Depression currently taking SSRIs
Recruiting
This open-label Phase IIa study is taking place at Hammersmith Medicines Research in London and will assess the safety, tolerability, efficacy and pharmacokinetics of BPL-003 co-administration alongside psychological support in patients with moderate-to-severe Treatment Resistant Depression who are also taking citalopram, escitalopram or sertraline.
This open-label Phase IIa study is taking place at King’s College in London, and will investigate the safety and efficacy of a single dose of BPL-003 given alongside an abstinence-oriented cognitive behavioural psychological intervention in patients with Alcohol Use Disorder.
Phase IIa monotherapy study of BPL-003 in patients with Treatment Resistant Depression
No longer recruiting
This open-label Phase IIa study is taking place at King’s College London and Hammersmith Medicines Research (HMR) in London, and will evaluate the safety and efficacy of a single dose of BPL-003 alongside psychological support in patients with moderate to severe Treatment Resistant Depression who have not shown an adequate response to prior standard antidepressant medication.
This Phase I, double-blind, placebo-controlled, randomised single ascending dose study is taking place in Manchester and Liverpool and will assess the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamic (PD) and subjective drug intensity (SDI) of intravenous doses of ELE-101 in healthy male and female adult participants.
This open-label Phase IIa is taking place in Manchester and Liverpool and will assess the pharmacodynamic (PD) effects of a single intravenous dose of ELE-101 in patients with depression.
Investigator Initiated Studies
We are committed to understanding the therapeutic potential of psychedelic drugs and support rigorous investigator-initiated research advancing psychedelic science.
We work in collaboration with select academic institutions and researchers.
For general information about our ongoing research activities, please use the contact form on our website or email us on medinfo@beckleypsytech.com
Links to other websites do not imply affiliation or endorsement. Beckley Psytech does not control and is not responsible for their content.
